{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T13:33:17Z","timestamp":1781789597908,"version":"3.54.5"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T00:00:00Z","timestamp":1647043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T00:00:00Z","timestamp":1647043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Self-financing project of Guangxi Health Commission of China","award":["Z2016293"],"award-info":[{"award-number":["Z2016293"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>This study aimed to verify the survival superiority of the combination of intraperitoneal perfusion and systemic chemotherapy over standard systemic chemotherapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 78 advanced gastric cancer patients with malignant ascites were randomly divided into D-SOX group (intraperitoneal infusion of docetaxel 30\u2009mg\/m<jats:sup>2<\/jats:sup> on d1 and d8, intravenous oxaliplatin 100\u2009mg\/m<jats:sup>2<\/jats:sup> on d1, and oral administration of S-1 on d1-d14) and DOS group (intravenous docetaxel 60\u2009mg\/m<jats:sup>2<\/jats:sup> on d1, intravenous oxaliplatin 100\u2009mg\/m<jats:sup>2<\/jats:sup> on d1, and oral administration of S-1 on d1-d14). Efficacy of both groups was evaluated every 2\u2009cycles with 21\u2009days as a cycle. The primary endpoint was overall survival, and the secondary endpoints were objective response rate, ascites control rate, negative conversion rate of ascites cytology, and side effects.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The median overall survival in D-SOX group was significantly higher than that in the DOS group (11.7 vs 10.3\u2009months, HR 0.52, 95%CI 0.31\u20130.86, <jats:italic>P<\/jats:italic> = 0.005). The ascites control rate in the D-SOX group was 58.9% and 30.8% in DOS group (95%CI 42.8\u201375.1% vs 95%CI 15.6\u201345.9%, <jats:italic>P<\/jats:italic> = 0.012). Besides, the adverse reactions were tolerable in both groups, and patients in the D-SOX group had lower grade 3\/4 blood toxicity than that in the DOS group (26% vs 54%, <jats:italic>P<\/jats:italic> = 0.01).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Compared with traditional systemic chemotherapy, docetaxel intraperitoneal infusion combined with chemotherapy has better therapeutic effect on gastric cancer ascites, with better survival benefit and tolerance and less hematological toxicity, which is worthy of further research and clinical application.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-022-06143-w","type":"journal-article","created":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T12:04:33Z","timestamp":1647086673000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["SOX combined with intraperitoneal perfusion of docetaxel compared with DOS regimen in the first-line therapy for advanced gastric cancer with malignant ascites: a prospective observation"],"prefix":"10.1186","volume":"23","author":[{"given":"Yehong","family":"Bin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenguang","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengsheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengxiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7408-9237","authenticated-orcid":false,"given":"Zhigang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,12]]},"reference":[{"issue":"3","key":"6143_CR1","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/ijc.28373","volume":"134","author":"I Thomassen","year":"2014","unstructured":"Thomassen I, van Gestel YR, van Ramshorst B, Luyer MD, Bosscha K, Nienhuijs SW, et al. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer. 2014;134(3):622\u20138. https:\/\/doi.org\/10.1002\/ijc.28373.","journal-title":"Int J Cancer."},{"issue":"39","key":"6143_CR2","doi-asserted-by":"publisher","first-page":"10936","DOI":"10.3748\/wjg.v21.i39.10936","volume":"21","author":"H Maeda","year":"2015","unstructured":"Maeda H, Kobayashi M, Sakamoto J. Evaluation and treatment of malignant ascites secondary to gastric cancer. World J Gastroenterol. 2015;21(39):10936\u201347. https:\/\/doi.org\/10.3748\/wjg.v21.i39.10936.","journal-title":"World J Gastroenterol."},{"key":"6143_CR3","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/978-1-4613-1247-5_4","volume":"82","author":"P Jacquet","year":"1996","unstructured":"Jacquet P, Sugarbaker PH. Peritoneal-plasma barrier. Cancer Treat Res. 1996;82:53\u201363.","journal-title":"Cancer Treat Res"},{"issue":"31","key":"6143_CR4","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","volume":"24","author":"E Van Cutsem","year":"2006","unstructured":"Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24(31):4991\u20137. https:\/\/doi.org\/10.1200\/JCO.2006.06.8429.","journal-title":"J Clin Oncol."},{"issue":"7","key":"6143_CR5","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1093\/jjco\/hyi109","volume":"35","author":"N Oriuchi","year":"2005","unstructured":"Oriuchi N, Nakajima T, Mochiki E, Takeyoshi I, Kanuma T, Endo K, et al. A new, accurate and conventional five-point method for quantitative evaluation of ascites using plain computed tomography in cancer patients. Jpn J Clin Oncol. 2005;35(7):386\u201390. https:\/\/doi.org\/10.1093\/jjco\/hyi109.","journal-title":"Jpn J Clin Oncol."},{"issue":"2","key":"6143_CR6","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s10120-015-0503-2","volume":"19","author":"HS Kim","year":"2016","unstructured":"Kim HS, Ryu MH, Zang DY, Ryoo BY, Yang DH, Cho JW, et al. Phase II study of docetaxel, oxaliplatin, and S-1 therapy in patients with metastatic gastric cancer. Gastric Cancer. 2016;19(2):579\u201385. https:\/\/doi.org\/10.1007\/s10120-015-0503-2.","journal-title":"Gastric Cancer."},{"issue":"10","key":"6143_CR7","doi-asserted-by":"publisher","first-page":"5975","DOI":"10.21873\/anticanres.12945","volume":"38","author":"M Shinkai","year":"2018","unstructured":"Shinkai M, Imano M, Chiba Y, Hiraki Y, Kato H, Iwama M, et al. Intraperitoneal and systemic chemotherapy for patients with gastric cancer with peritoneal metastasis: a phase II trial. Anticancer Res. 2018;38(10):5975\u201381. https:\/\/doi.org\/10.21873\/anticanres.12945.","journal-title":"Anticancer Res."},{"issue":"4","key":"6143_CR8","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2165\/11598890-000000000-00000","volume":"51","author":"C Hasovits","year":"2012","unstructured":"Hasovits C, Clarke S. Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics. Clin Pharmacokinet. 2012;51(4):203\u201324. https:\/\/doi.org\/10.2165\/11598890-000000000-00000.","journal-title":"Clin Pharmacokinet."},{"issue":"16 Pt 1","key":"6143_CR9","first-page":"5896","volume":"9","author":"RJ Morgan Jr","year":"2003","unstructured":"Morgan RJ Jr, Doroshow JH, Synold T, Lim D, Shibata S, Margolin K, et al. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics. Clin Cancer Res. 2003;9(16 Pt 1):5896\u2013901.","journal-title":"Clin Cancer Res."},{"issue":"5","key":"6143_CR10","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.3892\/or.19.5.1305","volume":"19","author":"S Fushida","year":"2008","unstructured":"Fushida S, Kinoshita J, Yagi Y, Funaki H, Kinami S, Ninomiya I, et al. Dual anti-cancer effects of weekly intraperitoneal docetaxel in treatment of advanced gastric cancer patients with peritoneal carcinomatosis: a feasibility and pharmacokinetic study. Oncol Rep. 2008;19(5):1305\u201310. https:\/\/doi.org\/10.3892\/or.19.5.1305.","journal-title":"Oncol Rep."},{"issue":"9","key":"6143_CR11","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1158\/1078-0432.CCR-06-1941","volume":"13","author":"AH Kyle","year":"2007","unstructured":"Kyle AH, Huxham LA, Yeoman DM, Minchinton AI. Limited tissue penetration of taxanes: a mechanism for resistance in solid tumors. Clin Cancer Res. 2007;13(9):2804\u201310. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-1941.","journal-title":"Clin Cancer Res."},{"issue":"3","key":"6143_CR12","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","volume":"9","author":"W Koizumi","year":"2008","unstructured":"Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9(3):215\u201321. https:\/\/doi.org\/10.1016\/S1470-2045(08)70035-4.","journal-title":"Lancet Oncol."},{"issue":"5","key":"6143_CR13","doi-asserted-by":"publisher","first-page":"973","DOI":"10.3892\/or.12.5.973","volume":"12","author":"S Yamagata","year":"2004","unstructured":"Yamagata S, Nakata B, Hirakawa K. Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 may be effective against peritoneal dissemination in gastric cancer. Oncol Rep. 2004;12(5):973\u20138. https:\/\/doi.org\/10.3892\/or.12.5.973.","journal-title":"Oncol Rep."},{"issue":"2","key":"6143_CR14","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00432-013-1563-5","volume":"140","author":"W Koizumi","year":"2014","unstructured":"Koizumi W, Kim YH, Fujii M, Kim HK, Imamura H, Lee KH, et al. Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). J Cancer Res Clin Oncol. 2014;140(2):319\u201328. https:\/\/doi.org\/10.1007\/s00432-013-1563-5.","journal-title":"J Cancer Res Clin Oncol."},{"issue":"Suppl 4","key":"6143_CR15","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1200\/jco.2013.31.4_suppl.60","volume":"31","author":"K Higuchi","year":"2013","unstructured":"Higuchi K, Koizumi W, Yamada Y, Nishikawa K, Gotoh M, Fuse N, et al. Randomized phase III study of S-1 plus oxaliplatin versus S-1 plus cisplatin for first-line treatment of advanced gastric cancer. J Cancer Res Clin Oncol. 2013;31(Suppl 4):60. https:\/\/doi.org\/10.1200\/jco.2013.31.4_suppl.60.","journal-title":"J Cancer Res Clin Oncol."},{"issue":"19","key":"6143_CR16","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1200\/JCO.2018.77.8613","volume":"36","author":"H Ishigami","year":"2018","unstructured":"Ishigami H, Fujiwara Y, Fukushima R, Nashimoto A, Yabusaki H, Imano M, et al. Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial. J Clin Oncol. 2018;36(19):1922\u20139. https:\/\/doi.org\/10.1200\/JCO.2018.77.8613.","journal-title":"J Clin Oncol."},{"issue":"5","key":"6143_CR17","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00280-009-0936-6","volume":"64","author":"DY Zang","year":"2009","unstructured":"Zang DY, Yang DH, Kim MJ, Jang KM, Hwang SW, Yoo KS, et al. Dose-finding study of docetaxel, oxaliplatin, and S-1 for patients with advanced gastric cancer. Cancer Chemother Pharmacol. 2009;64(5):877\u201383. https:\/\/doi.org\/10.1007\/s00280-009-0936-6.","journal-title":"Cancer Chemother Pharmacol."},{"issue":"1","key":"6143_CR18","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00280-018-3719-0","volume":"83","author":"Y Sato","year":"2019","unstructured":"Sato Y, Sagawa T, Ohnuma H, Hirakawa M, Takahashi Y, Hamaguchi K, et al. A dose-escalation study of docetaxel, oxaliplatin, and S-1 (DOS) as a first-line therapy for patients with unresectable metastatic gastric cancer. Cancer Chemother Pharmacol. 2019;83(1):161\u20137. https:\/\/doi.org\/10.1007\/s00280-018-3719-0.","journal-title":"Cancer Chemother Pharmacol."},{"issue":"18","key":"6143_CR19","doi-asserted-by":"publisher","first-page":"3354","DOI":"10.1002\/cncr.28204","volume":"119","author":"H Yamaguchi","year":"2013","unstructured":"Yamaguchi H, Kitayama J, Ishigami H, Emoto S, Yamashita H, Watanabe T. A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis. Cancer. 2013;119(18):3354\u20138. https:\/\/doi.org\/10.1002\/cncr.28204.","journal-title":"Cancer."},{"issue":"12","key":"6143_CR20","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1007\/s11605-012-2059-3","volume":"16","author":"M Imano","year":"2012","unstructured":"Imano M, Yasuda A, Itoh T, Satou T, Peng YF, Kato H, et al. Phase II study of single intraperitoneal chemotherapy followed by systemic chemotherapy for gastric cancer with peritoneal metastasis. J Gastrointest Surg. 2012;16(12):2190\u20136. https:\/\/doi.org\/10.1007\/s11605-012-2059-3.","journal-title":"J Gastrointest Surg."},{"issue":"1","key":"6143_CR21","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3892\/ol.2014.2651","volume":"9","author":"ZL Feng","year":"2015","unstructured":"Feng ZL, Chen LB, Liu ZY, Chen XJ, Ren XC, Liu YE, et al. DCF intraperitoneal and intravenous dual chemotherapy regimen for advanced gastric cancer: a feasibility study. Oncol Lett. 2015;9(1):491\u20137. https:\/\/doi.org\/10.3892\/ol.2014.2651.","journal-title":"Oncol Lett."},{"issue":"5","key":"6143_CR22","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s00280-013-2122-0","volume":"71","author":"S Fushida","year":"2013","unstructured":"Fushida S, Kinoshita J, Kaji M, Hirono Y, Goda F, Yagi Y, et al. Phase I\/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis. Cancer Chemother Pharmacol. 2013;71(5):1265\u201372. https:\/\/doi.org\/10.1007\/s00280-013-2122-0.","journal-title":"Cancer Chemother Pharmacol."},{"issue":"1","key":"6143_CR23","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/jso.22057","volume":"105","author":"Y Fujiwara","year":"2012","unstructured":"Fujiwara Y, Takiguchi S, Nakajima K, Miyata H, Yamasaki M, Kurokawa Y, et al. Intraperitoneal docetaxel combined with S-1 for advanced gastric cancer with peritoneal dissemination. J Surg Oncol. 2012;105(1):38\u201342. https:\/\/doi.org\/10.1002\/jso.22057.","journal-title":"J Surg Oncol."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06143-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-022-06143-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06143-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T12:07:15Z","timestamp":1647086835000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-022-06143-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,12]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["6143"],"URL":"https:\/\/doi.org\/10.1186\/s13063-022-06143-w","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,12]]},"assertion":[{"value":"7 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the principles of Helsinki Declaration and Good Clinical Practice and was approved by the Institutional Review Boards of Guangxi Medical University Medical Center. Written informed consents were obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consents were obtained from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"211"}}